Xspray Pharma: License agreement with Handa Therapeutics - Redeye
Redeye comments on Xspray’s out-licensing of certain patents covering the commercialization of a dasatinib product in the US and, subsequently, selected Asian markets.
ANNONS
Redeye comments on Xspray’s out-licensing of certain patents covering the commercialization of a dasatinib product in the US and, subsequently, selected Asian markets.
